Compare GENI & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GENI | NBTX |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United Kingdom | France |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2021 | 2018 |
| Metric | GENI | NBTX |
|---|---|---|
| Price | $6.19 | $36.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | $12.75 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 6.4M | 53.7K |
| Earning Date | 05-07-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.00 | $58.17 |
| Revenue Next Year | $20.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.83 | $4.46 |
| 52 Week High | $13.73 | $57.14 |
| Indicator | GENI | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.62 | 45.56 |
| Support Level | $5.68 | $30.15 |
| Resistance Level | $6.75 | $41.89 |
| Average True Range (ATR) | 0.49 | 2.49 |
| MACD | 0.00 | -0.28 |
| Stochastic Oscillator | 38.62 | 48.79 |
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas: Sports Technology and Services; Betting Technology, Content, and Services; and Media Technology, Content, and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content, and Services division. Geographically, the company derives a majority of its revenue from America.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.